269 related articles for article (PubMed ID: 28266807)
1. Comparative adherence to diabetes drugs: An analysis of electronic health records and claims data.
Flory J; Gerhard T; Stempniewicz N; Keating S; Rowan CG
Diabetes Obes Metab; 2017 Aug; 19(8):1184-1187. PubMed ID: 28266807
[TBL] [Abstract][Full Text] [Related]
2. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
[TBL] [Abstract][Full Text] [Related]
3. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
[TBL] [Abstract][Full Text] [Related]
4. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
5. Predictors of medication adherence in patients with type 2 diabetes mellitus.
Curkendall SM; Thomas N; Bell KF; Juneau PL; Weiss AJ
Curr Med Res Opin; 2013 Oct; 29(10):1275-86. PubMed ID: 23815104
[TBL] [Abstract][Full Text] [Related]
6. Part D coverage gap and adherence to diabetes medications.
Gu Q; Zeng F; Patel BV; Tripoli LC
Am J Manag Care; 2010; 16(12):911-8. PubMed ID: 21348561
[TBL] [Abstract][Full Text] [Related]
7. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
8. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
Bachmann KN; Roumie CL; Wiese AD; Grijalva CG; Buse JB; Bradford R; Zalimeni EO; Knoepp P; Dard S; Morris HL; Donahoo WT; Fanous N; Fonseca V; Katalenich B; Choi S; Louzao D; O'Brien E; Cook MM; Rothman RL; Chakkalakal RJ
Pharmacol Res Perspect; 2020 Oct; 8(5):e00637. PubMed ID: 32881317
[TBL] [Abstract][Full Text] [Related]
9. Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.
Payk SL; Drew RH; Smith JD; Jiroutek MR; Holland MA
Clin Ther; 2015 Jul; 37(7):1477-1482.e1. PubMed ID: 26024569
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Pediatric Type 2 Diabetes.
Smith JD; Mills E; Carlisle SE
Ann Pharmacother; 2016 Sep; 50(9):768-77. PubMed ID: 27307414
[TBL] [Abstract][Full Text] [Related]
11. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
12. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
14. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017.
Wilkinson S; Douglas I; Stirnadel-Farrant H; Fogarty D; Pokrajac A; Smeeth L; Tomlinson L
BMJ Open; 2018 Jul; 8(7):e022768. PubMed ID: 30056393
[TBL] [Abstract][Full Text] [Related]
15. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
Hansen RA; Farley JF; Droege M; Maciejewski ML
Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
[TBL] [Abstract][Full Text] [Related]
16. Intensification of medical management in type 2 diabetes: A real-world look at primary care practice.
Zekarias K; Davey C; Seaquist E
J Diabetes Complications; 2020 Jan; 34(1):107477. PubMed ID: 31711841
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.
Mahmoud F; Mullen A; Sainsbury C; Rushworth GF; Yasin H; Abutheraa N; Mueller T; Kurdi A
Eur J Clin Invest; 2023 Aug; 53(8):e13997. PubMed ID: 37002856
[TBL] [Abstract][Full Text] [Related]
18. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Zhou JB; Tang X; Han M; Yang J; Simó R
Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
[TBL] [Abstract][Full Text] [Related]
19. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK
Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299
[TBL] [Abstract][Full Text] [Related]
20. Trends in add-on medications following metformin monotherapy for type 2 diabetes.
Swart EC; Neilson LM; Munshi KD; Peasah SK; Henderson R; Good CB
J Manag Care Spec Pharm; 2022 Nov; 28(11):1253-1259. PubMed ID: 36282929
[No Abstract] [Full Text] [Related]
[Next] [New Search]